These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 8766645)

  • 21. [The kidneys and hypertension].
    Hausberg M; Mann J; Kühn K
    Dtsch Med Wochenschr; 2008 Sep; 133(37):1853-6. PubMed ID: 18770487
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How much must blood pressure be reduced in order to obtain the remission of chronic renal disease?
    Pisoni R; Remuzzi G
    J Nephrol; 2000; 13(3):228-31. PubMed ID: 10928301
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Do angiotensin converting enzyme and calcium channel blocker intervene in the progression of renal disease besides by lowering systemic hypertension?].
    Nagase M
    Nihon Rinsho; 1997 Aug; 55(8):2116-22. PubMed ID: 9284433
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders.
    Ellis D; Moritz ML; Vats A; Janosky JE
    Am J Hypertens; 2004 Oct; 17(10):928-35. PubMed ID: 15485756
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Vascular impact of anti-hypertensive treatment and renal protection].
    Mogensen CE
    Curr Med Res Opin; 2005; 21 Suppl 5():S23-8. PubMed ID: 16197649
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of calcium antagonists on glomerular hemodynamics and structure in experimental hypertension.
    Dworkin LD
    Am J Kidney Dis; 1991 May; 17(5 Suppl 1):89-93. PubMed ID: 2024683
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial.
    Perkins RM; Aboudara MC; Uy AL; Olson SW; Cushner HM; Yuan CM
    Am J Kidney Dis; 2009 Apr; 53(4):606-16. PubMed ID: 19216016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New clinical investigations with selective angiotensin II receptor blocker therapy in diabetes and renal disease.
    Ruilope LM
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2 Suppl):S29-31. PubMed ID: 17199217
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The use of angiotensin-converting enzyme inhibitors in chronic diffuse kidney diseases].
    Kutyrina IM; Tareeva IE; Gerasimenko OI; Rogov VA; Miroshnichenko NG
    Ter Arkh; 1995; 67(5):20-3. PubMed ID: 7638769
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    Ruilope LM
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S33-41. PubMed ID: 15868118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease.
    Weinberg AJ; Zappe DH; Ramadugu R; Weinberg MS
    J Hypertens Suppl; 2006 Mar; 24(1):S95-9. PubMed ID: 16601581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renal effects of calcium antagonists with special reference to manidipine hydrochloride.
    Rodicio JL
    Blood Press Suppl; 1996; 5():10-5. PubMed ID: 8973787
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RAS inhibition in hypertension.
    Ibrahim MM
    J Hum Hypertens; 2006 Feb; 20(2):101-8. PubMed ID: 16397519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    Rahman M; Pressel S; Davis BR; Nwachuku C; Wright JT; Whelton PK; Barzilay J; Batuman V; Eckfeldt JH; Farber M; Henriquez M; Kopyt N; Louis GT; Saklayen M; Stanford C; Walworth C; Ward H; Wiegmann T
    Arch Intern Med; 2005 Apr; 165(8):936-46. PubMed ID: 15851647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulation of glomerular filtration in essential hypertension: role of abnormal Na+ transport and atrial natriuretic peptide.
    Semplicini A; Ceolotto G; Sartori M; Maresca A; Baritono E; De Toni R; Paparella I; Calò L
    J Nephrol; 2002; 15(5):489-96. PubMed ID: 12455714
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal haemodynamics in hypertension: effects of antihypertensive drugs.
    Dupont AG
    J Hum Hypertens; 1993 Feb; 7 Suppl 1():S42-5. PubMed ID: 8487249
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal vascular effects of calcium channel blockers in hypertension.
    Benstein JA; Dworkin LD
    Am J Hypertens; 1990 Dec; 3(12 Pt 2):305S-312S. PubMed ID: 2078317
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Calcium antagonists for initial therapy of hypertension.
    Frohlich ED
    Heart Lung; 1989 Jul; 18(4):370-6. PubMed ID: 2663785
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [CCB uptitration is superior to ARB uptitration in CKD patients who do not reach target blood pressure with ARB/CCB combined therapy].
    Ishii T; Kawamura T; Tsuboi N; Hosoya T
    Nihon Jinzo Gakkai Shi; 2010; 52(7):945-51. PubMed ID: 21077346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Renal effects of conversion enzyme inhibitors].
    Ritz E; Nowack R; Reisch C; Beutel G
    Klin Wochenschr; 1991; 69 Suppl 24():50-7; discussion 57-8. PubMed ID: 1865633
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.